Eric Raymond
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Viral-associated cancers and disorders
-
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 7
- Cancer Treatment and Pharmacology 4
- PARP inhibition in cancer therapy 2
- Viral-associated cancers and disorders 1
- Pancreatic and Hepatic Oncology Research 1
-
- Prostate Cancer Treatment and Research 2
- Lung Cancer Treatments and Mutations 2
- Co-authors
- Sandrine Faivre (4 shared papers)Jean Pierre Armand (1 shared paper)Didier Samuel (1 shared paper)Henri Bismuth (1 shared paper)V. Tricottet (1 shared paper)M Reynès (1 shared paper)Tu Nguyen‐Ngoc (1 shared paper)Christian Gespach (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Cancer (1 paper)Current Opinion in Oncology (1 paper)Drugs (1 paper)Bulletin du Cancer (1 paper)
- Partner nations
- FranceUnited StatesSwitzerland
In The Last Decade
Eric Raymond
8 papers receiving 376 citations
Peers
Comparison fields: 5 of 59
- Oncology 198
- Pulmonary and Respiratory Medicine 109
- Pathology and Forensic Medicine 34
- Molecular Biology 140
- Organic Chemistry 59
Countries citing papers authored by Eric Raymond
This map shows the geographic impact of Eric Raymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Raymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Raymond more than expected).
Fields of papers citing papers by Eric Raymond
This network shows the impact of papers produced by Eric Raymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Raymond. The network helps show where Eric Raymond may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Raymond, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 335 | |
| 2 | 1995 | 31 | |
| 3 | [Preclinical studies of oxaliplatin in combination chemotherapy]. | 2001 | 10 |
| 4 | 2015 | 8 | |
| 5 | 2004 | 2 | |
| 6 | 2004 | 1 | |
| 7 | 2009 | 1 | |
| 8 | 2004 | 1 |
About Eric Raymond
Eric Raymond is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry, Surgery and Molecular Biology, having authored 8 papers that have together received 389 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Prostate Cancer Treatment and Research (2 papers), Lung Cancer Treatments and Mutations (2 papers), PARP inhibition in cancer therapy (2 papers), Viral-associated cancers and disorders (1 paper), Pancreatic and Hepatic Oncology Research (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Oncology (198 citations), Pulmonary and Respiratory Medicine (109 citations), Pathology and Forensic Medicine (34 citations), Molecular Biology (140 citations) and Organic Chemistry (59 citations). Eric Raymond has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Sandrine Faivre, Jean Pierre Armand, Didier Samuel, Henri Bismuth, V. Tricottet, M Reynès, Tu Nguyen‐Ngoc, Christian Gespach, A M Coudray and Christophe Louvet. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Current Opinion in Oncology, Drugs and Bulletin du Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.